Muses Labs Brings Software Expertise to Alzheimer’s Disease Therapeutics

Muses Labs Brings Software Expertise to Alzheimer’s Disease Therapeutics
alzheimer's softwareMuses Labs, based at Research Triangle Park in Raleigh, North Carolina, creates software-based systems to enable personalized therapy for the treatment of complex diseases. The company recently announced the development of its first offering for addressing Alzheimer's disease. The combination therapy it implements is based on a broad understanding of the pathogenesis of Alzheimer's disease, and aims to achieve Metabolic Enhancement for NeuroDegeneration (MEND) by targeting multiple interrelated biological mechanisms simultaneously. Muses Labs will soon launch a two-year observational study to test its methodology, targeting 200+ participants with Alzheimer's disease. The company says this approach to Alzheimer's disease (AD) is based on the molecular biology of the brain and the bodily systems that support it. Decades of scientific research from around the globe are brought together and incorporated into MEND. Muses Labs combines medical expertise with software algorithms. Its algorithms figure out the optimal personalized therapy for an individual, and enables their physician to prescribe the therapy. Muses Labs software then motivates an individual's adherence to the therapy it recommends. The financial cost of dealing with Alzheimer's disease annually in the USA is now estimated to exceed $200 billion, and doesn't include the emotional expense borne by family members and caregivers of persons with Alzheimer's dise
Subscribe or to access all post and page content.